Evidence map›Paper›PMID 28352653›Full record

ArticleJCI insight2017

Defective postsecretory maturation of MUC5B mucin in cystic fibrosis airways.

Lubna H Abdullah, Jessica R Evans, T Tiffany Wang, Amina A Ford, Alexander M Makhov, Kristine Nguyen, Raymond D Coakley, Jack D Griffith, C William Davis, Stephen T Ballard and 1 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Normalization of Muc5b ameliorates airway mucus plugging during persistentAmerican journal of physiology. Lung cellular and molecular physiology · 2024
    Article
  4. Article
  5. Acquired dysfunction of CFTR underlies cystic fibrosis-like disease of the canine gallbladder.American journal of physiology. Gastrointestinal and liver physiology · 2024
    Article
  6. Article
  7. Article
  8. Specialized proresolving mediator resolvin E1 corrects the altered cystic fibrosis nasal epithelium cilia beating dynamics.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  9. Review
  10. SNSP113 (PAAG) improves mucociliary transport and lung pathology in the Scnn1b-Tg murine model of CF lung disease.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2023
    Article
  11. Article
  12. Review
  13. Mucolytic bacteria: prevalence in various pathological diseases.World journal of microbiology & biotechnology · 2021
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Mucus, mucins, and cystic fibrosis.Pediatric pulmonology · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Lubna H AbdullahCystic Fibrosis and Pulmonary Diseases Research and Treatment Center, University of North Carolina at Chapel Hill, North Carolina, USA.
Jessica R EvansDepartment of Physiology and Biophysics, College of Medicine, University of South Alabama, Mobile, Alabama, USA.
T Tiffany WangCystic Fibrosis and Pulmonary Diseases Research and Treatment Center, University of North Carolina at Chapel Hill, North Carolina, USA.
Amina A FordCystic Fibrosis and Pulmonary Diseases Research and Treatment Center, University of North Carolina at Chapel Hill, North Carolina, USA.
Alexander M MakhovLineberger Cancer Center, University of North Carolina at Chapel Hill, North Carolina, USA.
Kristine NguyenCystic Fibrosis and Pulmonary Diseases Research and Treatment Center, University of North Carolina at Chapel Hill, North Carolina, USA.
Raymond D CoakleyCystic Fibrosis and Pulmonary Diseases Research and Treatment Center, University of North Carolina at Chapel Hill, North Carolina, USA.
Jack D GriffithLineberger Cancer Center, University of North Carolina at Chapel Hill, North Carolina, USA.
C William DavisCystic Fibrosis and Pulmonary Diseases Research and Treatment Center, University of North Carolina at Chapel Hill, North Carolina, USA.
Stephen T BallardDepartment of Physiology and Biophysics, College of Medicine, University of South Alabama, Mobile, Alabama, USA.
Mehmet KesimerCystic Fibrosis and Pulmonary Diseases Research and Treatment Center, University of North Carolina at Chapel Hill, North Carolina, USA.
University of North Carolina at Chapel Hill · USUniversity of South Alabama · US

Funding

Vironomics and Biostatistics CoreP01CA019014 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BLOSSOM A DAMANIA, NANCY JOAN RAAB-TRAUB · 1985 to 2026
$43.8M
The role of mucin-protein interactions in the innate defense of the lungR01HL103940 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KESIMER, MEHMET · 2010 to 2014
$1.8M
NCI NIH HHS P01 CA019014NHLBI NIH HHS R01 HL103940
6 · The paper itself

Abstract

In cystic fibrosis (CF), airway mucus becomes thick and viscous, and its clearance from the airways is impaired. The gel-forming mucins undergo an ordered "unpacking/maturation" process after granular release that requires an optimum postsecretory environment, including hydration and pH. We hypothesized that this unpacking process is compromised in the CF lung due to abnormal transepithelial fluid transport that reduces airway surface hydration and alters ionic composition. Using human tracheobronchial epithelial cells derived from non-CF and CF donors and mucus samples from human subjects and domestic pigs, we investigated the process of postsecretory mucin unfolding/maturation, how these processes are defective in CF airways, and the probable mechanism underlying defective unfolding. First, we found that mucins released into a normal lung environment transform from a compact granular form to a linear form. Second, we demonstrated that this maturation process is defective in the CF airway environment. Finally, we demonstrated that independent of HCO

Indexed as

AmilorideAnimalsBronchiBumetanideCells, CulturedCystic FibrosisHumansIn Vitro TechniquesMucin-5BSwineTrachea5-dimethylamilorideAmilorideBumetanideMUC5B protein, humanMucin-5B

Identifiers

PMID28352653
PMCPMC5358479
OpenAlexW2599860237

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.